JAMA Intern Med

Empagliflozin and dapagliflozin yield comparable kidney outcomes in T2DM

January 28, 2025

Empagliflozin and dapagliflozin are equally effective for kidney protection in T2DM, suggesting that clinicians could choose either medication based on individual patient needs and preferences.

Study details: This nationwide cohort study emulated a target trial using Danish health care data to compare kidney outcomes between empagliflozin and dapagliflozin in adults with T2DM receiving antihyperglycemic treatment. The study included 32,819 individuals initiating empagliflozin and 17,464 initiating dapagliflozin, followed for up to 6 years.

Results: No significant differences were found in 6-year risks of acute kidney injury (18.2% vs. 18.5%; risk ratio [RR], 0.98; 95% confidence interval [CI], 0.91-1.06), chronic kidney disease stages G3 to G5 (11.8% vs. 12.1%; RR, 0.97; 95% CI, 0.89-1.05), or chronic kidney disease progression (5.3% vs. 5.7%; RR 0.94; 95% CI, 0.56-1.58) between the two groups. Both drugs exhibited similar effectiveness in reducing long-term kidney risks.

Source:

Bonnesen K, et al. (2025, January 21). JAMA Intern Med. Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/39836391/